Neuphoria TherapeuticsNEUP
13F holders, Q4 2024 (December 31)8holders
$3.43avg. 13F price*
At the end of Q4 2024, 8 institutions reported holding Neuphoria Therapeutics Inc. (NEUP) in their 13F filings. The largest holders were Lynx1 Capital Management LP ($157K), Jane Street Group, LLC ($46K) and Merck & Co., Inc. ($34K).
- Company
- Neuphoria Therapeutics Inc.
- CUSIP
- 64136E102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $239K |
| Exits | 0 | $0 |
Ownership 8 holders
| Lynx1 Capital Management LP | 0.06% | New | 45,806 | $157K |
| Jane Street Group, LLC | 0.00% | New | 13,311 | $46K |
| Merck & Co., Inc. | 0.01% | — | 10,027 | $34K |
| Bank of America Corp. | 0.00% | New | 6,484 | $22K |
| UBS Group AG | 0.00% | New | 2,978 | $10K |
| Rhumbline Advisers | 0.00% | New | 1,106 | $4K |
| Morgan Stanley | 0.00% | New | 7 | $24 |
| Hanson & Doremus Investment Management | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is NEUP's weight in each manager's 13F, not the share of Neuphoria Therapeutics Inc. the manager owns.